NewAmsterdam Pharma Co NV
For the period ended Jun 30, 2024. Filed Aug 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 7, 2024
NAMS$19.18+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows
| For the six months ended June 30, | ||
|---|---|---|
| 2024 | 2023 | |
| (In thousands of USD) | ||
| Operating activities: | ||
| Loss for the period | (132,774) | (80,309) |
| Non-cash adjustments to reconcile loss before tax to net cash flows: | ||
| Depreciation and amortization | 34 | 22 |
| Non-cash rent expense | 3 | 3 |
| Fair value change - derivative earnout and warrants | 29,258 | 6,525 |
| Foreign exchange (gains)/losses | 3,412 | (2,995) |
| Share-based compensation | 16,208 | 13,174 |
| Changes in working capital: | ||
| Changes in prepayments (current and non-current) and other receivables | (8,276) | 4,038 |
| Changes in accounts payable | (11,656) | 1,410 |
| Changes in accrued expenses and other current liabilities | (1,110) | 1,925 |
| Changes in deferred revenue | (3,680) | (4,961) |
| Net cash (used in)/provided by operating activities | (108,581) | (61,168) |
| Investing activities: | ||
| Purchase of property, plant and equipment, including internal use software | (594) | (12) |
| Net cash used in investing activities | (594) | (12) |
| Financing activities: | ||
| Proceeds from offering of Ordinary Shares and Pre-Funded Warrants | 190,481 | — |
| Transaction costs on issue of Ordinary Shares and Pre-Funded Warrants | (515) | — |
| Proceeds from exercise of warrants | 13,421 | 8,621 |
| Proceeds from exercise of options | 440 | 105 |
| Payment of withholding taxes related to net share settlement of exercised options | (989) | — |
| Net cash provided by financing activities | 202,838 | 8,726 |
| Net change in cash | 93,663 | (52,454) |
| Foreign exchange differences | (3,405) | 1,432 |
| Cash at the beginning of the period | 340,450 | 467,728 |
| Cash at the end of the period | 430,708 | 416,706 |
| Noncash financing and investing activities | ||
| Right-of-use assets obtained in exchange for new operating lease liabilities | 562 | — |
See notes to consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.